Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 3 3Phase 2/3 2Phase EARLY_PHASE1 1Phase 1/2 1

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Plasma cell 1Genitourinary 1

Conditions

Nephrotic Syndrome 1Neoplasm Metastasis 1Kidney Diseases 1Gastrointestinal Diseases 1Familial Mediterranean Fever 1Carcinoma, Hepatocellular 1Arthritis, Rheumatoid 1Amyloidosis 1

Interventions

Oxaliplatin 49Fluorouracil 46Capecitabine 41Cisplatin 36Gemcitabine 29Leucovorin 27Bevacizumab 21Drug Therapy 20Paclitaxel 15Folfox protocol 15Radiotherapy 14Irinotecan 14apatinib 11Neoadjuvant Therapy 11Docetaxel 11sintilimab 9S 1 (combination) 9Sorafenib 8Nivolumab 8Trastuzumab 7Surgical Procedures, Operative 7Magnetic Resonance Spectroscopy 7lenvatinib 6atezolizumab 6XELOX 6Cetuximab 6Albumin-Bound Paclitaxel 6130-nm albumin-bound paclitaxel 6tislelizumab 5pembrolizumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Pharmaceutical Preparations × Gastrointestinal × Clear all
NCT07309419 2025-12-30

Cocktail-001

Shanghai Zhongshan Hospital

Phase 2/3 Not yet recruiting
222 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT00035334 2006-02-14

Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis

Bellus Health Inc. - a GSK company

Phase 2/3 Completed
150 enrolled
GastrointestinalGenitourinaryPlasma cell

Amyloidosis, Arthritis, Rheumatoid, Gastrointestinal Diseases, Kidney Diseases, Neoplasm Metastasis, Nephrotic Syndrome, Familial Mediterranean Fever

Data powered by HemOnc (CC BY 4.0) Colophon âš¡